Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
VYNE
Valuation N/A
VYNE Therapeutics Inc.
Price$27.85
Model IV—
P/IV—
Market implies +139.1%/yr
vs model +2.0% · above model
WAT
Deeply overvalued
WATERS CORP /DE/
Price$421.63
Model IV$153.22
P/IV2.50
Premium +175%
Return to IV: -63.7%
Owner yield 2.1%
10-yr IRR -2.4% · moderate
Market implies +18.8%/yr
vs model +6.2% · above model
WGS
Deeply overvalued
GeneDx Holdings Corp.
Price$85.27
Model IV$28.45
P/IV1.83
Premium +200%
Return to IV: -66.6%
Market implies +15.5%/yr
vs model +19.1% · below model
WHWK
Valuation N/A
Whitehawk Therapeutics, Inc.
Price$4.11
Model IV—
P/IV—
Market implies +74.9%/yr
vs model +2.0% · above model
WOK
Deeply undervalued
WORK Medical Technology Group LTD
Price$1.88
Model IV$1.61
P/IV0.06
Premium +17%
Return to IV: -14.2%
Market implies -0.2%/yr
vs model +2.0% · in line
WRBY
Valuation N/A
Warby Parker Inc.
Price$24.71
Model IV—
P/IV—
Market implies +56.1%/yr
vs model +11.9% · above model
WST
Deeply overvalued
WEST PHARMACEUTICAL SERVICES INC
Price$362.31
Model IV$123.32
P/IV2.62
Premium +194%
Return to IV: -66.0%
Owner yield 1.5%
10-yr IRR -6.7% · steady
Market implies +19.0%/yr
vs model +5.7% · above model
WVE
Valuation N/A
Wave Life Sciences Ltd.
Price$4.59
Model IV—
P/IV—
Market implies +90.1%/yr
vs model +2.0% · above model
XAIR
Deeply overvalued
Beyond Air, Inc.
Price$3.14
Model IV$0.58
P/IV0.80
Premium +444%
Return to IV: -81.6%
Market implies +9.0%/yr
vs model +43.5% · below model
XBIO
Deeply overvalued
Xenetic Biosciences, Inc.
Price$3.90
Model IV$2.04
P/IV1.54
Premium +91%
Return to IV: -47.7%
Market implies +7.6%/yr
vs model +26.5% · below model
XBIT
Valuation N/A
XBiotech Inc.
Price$2.19
Model IV—
P/IV—
Market implies +31.0%/yr
vs model +15.0% · above model
XCUR
Valuation N/A
EXICURE, INC.
Price$1.31
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +15.0% · above model
XENE
Valuation N/A
Xenon Pharmaceuticals Inc.
Price$58.65
Model IV—
P/IV—
Market implies +111.3%/yr
vs model +2.0% · above model
XERS
Deeply undervalued
Xeris Biopharma Holdings, Inc.
Price$7.45
Model IV$17.20
P/IV0.36
Discount 57%
Return to IV: +130.8%
Market implies -15.7%/yr
vs model +50.0% · below model
XFOR
Valuation N/A
X4 Pharmaceuticals, Inc
Price$3.62
Model IV—
P/IV—
Market implies +38.9%/yr
vs model +15.0% · above model
XGN
Deeply overvalued
EXAGEN INC.
Price$7.35
Model IV$1.92
P/IV2.59
Premium +283%
Return to IV: -73.9%
Market implies +17.3%/yr
vs model +8.4% · above model
XLO
Fairly valued
Xilio Therapeutics, Inc.
Price$8.93
Model IV$8.45
P/IV1.00
Premium +6%
Return to IV: -5.3%
Market implies -7.3%/yr
vs model +15.0% · below model
XNCR
Valuation N/A
Xencor Inc
Price$24.41
Model IV—
P/IV—
Market implies +65.5%/yr
vs model +2.0% · above model
XOMA
Valuation N/A
XOMA Royalty Corp
Price$40.17
Model IV—
P/IV—
Market implies +69.6%/yr
vs model +2.0% · above model
XOMAO
Valuation N/A
XOMA Royalty Corp
Price$25.00
Model IV—
P/IV—
Market implies +72.6%/yr
vs model +2.0% · above model
XOMAP
Valuation N/A
XOMA Royalty Corp
Price$24.98
Model IV—
P/IV—
Market implies +37.2%/yr
vs model +2.0% · above model
XRAY
Deeply overvalued
DENTSPLY SIRONA Inc.
Price$10.46
Model IV$4.64
P/IV2.26
Premium +125%
Return to IV: -55.6%
Owner yield 9.8%
10-yr IRR 17.8% · steady
Market implies +16.2%/yr
vs model +5.5% · above model
XRTX
Valuation N/A
XORTX Therapeutics Inc.
Price$2.07
Model IV—
P/IV—
XTLB
Valuation N/A
XTL BIOPHARMACEUTICALS LTD
Price$2.56
Model IV—
P/IV—
Market implies +147.5%/yr
vs model +15.0% · above model
XTNT
Deeply undervalued
Xtant Medical Holdings, Inc.
Price$0.35
Model IV$1.96
P/IV0.24
Discount 82%
Return to IV: +467.8%
Market implies -9.4%/yr
vs model +20.3% · below model
YDES
Valuation N/A
YD Bio Ltd
Price$4.00
Model IV—
P/IV—
Market implies +43.8%/yr
vs model +30.6% · above model
ZBH
Deeply undervalued
ZIMMER BIOMET HOLDINGS, INC.
Price$95.36
Model IV$203.72
P/IV0.40
Discount 53%
Return to IV: +113.6%
Owner yield 7.1%
10-yr IRR 14.6% · moderate
Market implies -3.2%/yr
vs model +7.8% · below model
ZBIO
Valuation N/A
Zenas BioPharma, Inc.
Price$31.12
Model IV—
P/IV—
Market implies +92.3%/yr
vs model +2.0% · above model
ZJYL
Valuation N/A
Jin Medical International Ltd.
Price$2.07
Model IV—
P/IV—
Market implies +54.5%/yr
vs model +2.0% · above model
ZLAB
Valuation N/A
Zai Lab Ltd
Price$24.14
Model IV—
P/IV—
Market implies +37.3%/yr
vs model +33.5% · above model
ZNTL
Valuation N/A
Zentalis Pharmaceuticals, Inc.
Price$3.51
Model IV—
P/IV—
Market implies +22.0%/yr
vs model +15.0% · above model
ZTS
Undervalued
Zoetis Inc.
Price$71.40
Model IV$88.64
P/IV0.91
Discount 19%
Return to IV: +24.1%
Owner yield 5.7%
10-yr IRR 11.9% · moderate
Market implies +4.1%/yr
vs model +8.7% · below model
ZURA
Valuation N/A
Zura Bio Ltd
Price$5.21
Model IV—
P/IV—
ZVRA
Fairly valued
ZEVRA THERAPEUTICS, INC.
Price$12.05
Model IV$12.28
P/IV0.94
Discount 2%
Return to IV: +1.9%
Market implies -5.2%/yr
vs model +38.8% · below model
ZYBT
Deeply overvalued
Zhengye Biotechnology Holding Ltd
Price$1.55
Model IV$0.39
P/IV2.18
Premium +297%
Return to IV: -74.8%
Market implies +24.0%/yr
vs model +10.0% · above model
ZYME
Deeply overvalued
Zymeworks Inc.
Price$26.24
Model IV$8.98
P/IV2.80
Premium +192%
Return to IV: -65.8%
Market implies +9.7%/yr
vs model +41.2% · below model